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Abstract
Background: Knowing the risk factors of CKD should be able to identify at risk populations. We thus aimed to
develop and validate a simplified clinical prediction score capable of indicating those at risk.
Methods: A community-based cross-sectional survey study was conducted. Ten provinces and 20 districts were
stratified-cluster randomly selected across four regions in Thailand and Bangkok. The outcome of interest was
chronic kidney disease stage I to V versus non-CKD. Logistic regression was applied to assess the risk factors.
Scoring was created using odds ratios of significant variables. The ROC curve analysis was used to calibrate the cut-
off of the scores. Bootstrap was applied to internally validate the performance of this prediction score.
Results: Three-thousand, four-hundred and fifty-nine subjects were included to derive the prediction scores. Four
(i.e., age, diabetes, hypertension, and history of kidney stones) were significantly associated with the CKD. Total
scores ranged from 4 to 16 and the score discrimination was 77.0%. The scores of 4-5, 6-8, 9-11, and ≥ 12
correspond to low, intermediate-low, intermediate-high, and high probabilities of CKD with the likelihood ratio
positive (LR
+) of 1, 2.5 (95% CI: 2.2-2.7), 4.9 (95% CI: 3.9 - 6.3), and 7.5 (95% CI: 5.6 - 10.1), respectively. Internal
validity was performed using 200 repetitions of a bootstrap technique. Calibration was assessed and the difference
between observed and predicted values was 0.045. The concordance C statistic of the derivative and validated
models were similar, i.e., 0.770 and 0.741.
Conclusions: A simplified clinical prediction score for estimating risk of having CKD was created. The prediction
score may be useful in identifying and classifying at riskpatients. However, further external validation is needed to
confirm this.
Background
Chronic kidney disease (CKD) is a precursor to end stage
kidney disease (ESKD), which requires major intervention
in the form of dialysis or transplant. The prevalence of
the ESKD in Thailand from 2002 to 2006 was about 220-
286/million population throughout the country [1]. CKD
tends to increase according to the increased prevalence
of diabetes, hypertension, and economic development
within a region. Early identification and targeting of indi-
viduals with CKD should be encouraged for the purpose
of instituting intervention strategies, such as low-protein
dietary changes, close monitoring of blood pressure,
control of blood sugar levels, health-monitoring pro-
grams, education, exercise, and so on[2].
If the risk factors of CKD are known, one should be able
to predict the probability of at risk individuals developing
CKD, and thus identify at risk populations. Although
many previous studies have assessed the risk factors of
CKD in general populations, few non-Asian-based studies
have constructed prediction scores using cumulative com-
binations of risk factors [3-6]. A hospital-based study by
Hemmelgarn et al[4] studied subjects of ages 66 years or
older, and thus applying the score to general population
will result in poor validity. Two community-based obser-
vational studies [3,5] developed and validated a simple
algorithm for CKD stage III or higher based on two demo-
graphic data and six medical histories. Among those medi-
cal histories, few variables (i.e., a history of heart disease,
heart failure, and peripheral vascular disease) were not
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were assessed, their validity was still questionable, particu-
larly in developing countries where education & knowl-
edge about the diseases are limited. Thus the scores are
not qualified as for a concept of developing a simplified
prediction score [7-9], in which the scores should not con-
tain many variables and which should be easily and validly
measured. Some prediction scores for diabetes had also
been used to predict CKD, but discriminative ability was
low[6]. We therefore conducted a study to develop and
validate a simplified clinical prediction score for estimate
risk of developing CKD in the Thai general population.
The scores would aid general-practice physicians in identi-
fying individuals who are at risk of having CKD and
should have further investigation and management.
Methods
Studied population
This study was part of a community-based, cross-sectional
survey study of CKD prevalence where the details of the
research methodologies have been clearly described else-
w h e r e[ 1 0 ] ,s oa r eo n l yb r i e f l yd e s c r i b e da sf o l l o w s :T h e
study included subjects who were 18 years or older, had
no menstruation period for at least a week prior to the
examination date if women, and whom were willing parti-
cipants of the study and provided signed consent forms.
Ten provinces and 20 districts were selected across four
regions of Thailand (i.e., Northern, Northeastern, Central,
Southern) and Bangkok using a stratified-cluster random
sampling. Subjects in the sample districts were then ran-
domly selected and stratified by age and sex. The study
was approved by two Institutional Review Boards (IRBs),
i.e., the IRB of the Faculty of Medicine at Ramathibodi
Hospital, Mahidol University, and the IRB of the Ministry
of Public Health.
Measurement of risk factors
Physical examinations (i.e., respiratory rate, weight, height,
waist & hip circumference, and blood pressure) were col-
lected by nurses at each site. Blood samples, after eight-
hour overnight fasting, were collected for blood chemistry
tests (i.e., serum blood sugar, triglycerides (TRIG), total
cholesterol (TC), high-density lipoprotein cholesterol
(HDL-c), low-density lipoprotein cholesterol (LDL-c), uric
acid (UA), serum creatinine, and complete blood count
(Hb, WBC). Urine tests (i.e., micro-, macro-protein and
urinary analysis) were also collected. Hematuria was
defined as the presence of more than 5 red blood cells per
high-power field, and microalbuminuria was defined as an
albumin-creatinine ratio of 30 to 300 mg/g. Hypertension,
diabetes, and high cholesterol, were classified based on
one of following conditions: a history of illnesses, relevant
medicines used (e.g., non-steroidal anti-inflammatory drug
(NSAID)), or laboratory tests/physical examinations.
Anemia was diagnosed if subjects had hemoglobin levels
of less than 10 g/dl. History of kidney stone was measured
by self-reporting kidney stone.
Outcome measurements
Serum creatinine was measured using the modified Kinetic
Jaffe (KJ) method and then standardized by the isotope
dilution mass spectrometry (IDMS) method. The esti-
mated glomerular filtration rate (GFR) was then calculated
using an MDRD equation for IDMS traceable serum crea-
tinine values as follows[11]: eGFR (mL/min/1.73 m
2)=
175 × (SCr)
-1.154 ×( A g e )
-0.203 ×( 0 . 7 4 2i ff e m a l e ) .
CKD was defined [12] as stage I & II if GFR ≥ 90 and
GFR 60-89 ml/min/1.73 m
2 with haematuria and/or albu-
min-creatinine ratio 30 mg/g or greater, stage III, IV, and
V if the GFR of 30-59, 15-29, and < 15 ml/min/1.73 m
2
respectively, regardless of kidney damage. The CKD stages
I-V were combined and then compared with non-CKD in
analysis.
Statistical analysis
Derivative phase
Data from the 10 provinces were used to derive a simpli-
fied clinical prediction score. Weighted logistic regression
for a multi-stage sampling survey data was applied to
derive the parsimonious model. The three-stage weight
was calculated briefly as follows: 1/[probability of sampling
provinces]×[probability of sampling districts]×[probability
of sampling subjects]]. The probability of sampling pro-
vinces was estimated by the number of sample provinces
divided by the total number of provinces in that stratum
(region). The probability of sampling districts was calcu-
lated by the number of sample districts divided by the
total number of districts in the sample province. Finally,
the probability of sampling subjects was the number of
subjects divided by the size of the population of the sam-
ple district. Data from the Thai population census of 2007,
Ministry of Interior [13] was used for population size.
Factors with p values < 0.15 in a univariate analysis were
considered to be simultaneously included in the multivari-
ate logistic equation. Model selection was performed using
F-tests, and thus only significant variables were kept in the
final model. Receiver operating characteristic (ROC) analy-
sis was applied to simplify the model and the area under
the ROC curve or known as the concordance (C) statistic
was estimated. The C statistic of models with and without
a particular variable were then compared; if dropping that
variable did not significantly reduce the explanation of the
CKD, that variable was omitted in the final parsimonious
model. Model’s performances of the final model measured
by the goodness of fit statistic and the C statistic were
assessed. The odds ratios (OR) of the final model were
then estimated and rounded off in order to simplify the
scores, and these were used to construct the scoring
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variable and summed up as total scores. Score perfor-
mances, i.e., sensitivity, specificity, and positive and nega-
tive likelihood ratios (LR
+/LR
-) were calculated according
to each possible total score. The total scores were then
classified according to the strength of the LR
+ [14]. Post
test probability was next estimated.
Validation phase
Internal validation of the prediction scores was checked
using a bootstrap of 200 repetitions [15,16]. For each sam-
ple of the bootstrap, the logistic model was fitted based on
significant variables in the derivative phase, and prediction
scores based on ORs and parameters (i.e. predicted prob-
ability and the C statistic) were estimated. The correlation
between the observed and predicted values of CKD was
assessed using the Somer’D correlation, called Dboot. Cali-
bration of the model was then assessed by subtracting the
original Somer’D correlation from the mean Dboot. Discri-
mination of the model was assessed by comparing the ori-
ginal C statistic versus an average C statistic from the
bootstraps. All analyses were performed using STATA 11.
A p value < 0.05 was considered statistically significant.
Results
Derivative phase
All 3,459 subjects from the CKD prevalence study[10]
were included to derive the prediction scores. The charac-
teristics of the subjects were described (table 1), i.e., the
mean age was 45.2 years (SE = 0.79), 54.5% were females
and 63.9% had BMI less than 25 kg/m
2. The mean waist-
hip ratio was 0.81 (SE = 0.01). The majority of subjects
had never smoked (64.1%), and some of them were cur-
rently or ever alcohol drinkers (58.9%). The prevalence of
diabetes, hypertension, and high cholesterol were frequent,
i.e., 11.9%, 27.5%, and 26.4%, respectively. However, a his-
tory of heart disease, cerebrovascular accident, and history
of kidney stones were quite low, i.e., 3.4%, 1.4%, and 5.0%
respectively. Interestingly, history of taking NSAID, and
traditional medicines were as high as 44.7% and 33.5%,
respectively. Mean serum creatinine in males and females
were 1.1 (SE = 0.02) and 0.8 (SE = 0.02) respectively. The
CKD prevalence was 17.5% (95% confidence interval (CI):
14.6% - 20.5%).
Sixteen variables were considered in the univariate ana-
lysis, as shown in Table 1. All variables (except gender,
smoking, exercise, LDL, and NSAIDs) with p values < 0.15
were simultaneously included in a multivariate model. The
final model contained only 4 variables (i.e., age, diabetes,
hypertension, and history of kidney stones), and their ORs
are listed in Table 2. The scoring scheme for each variable
was constructed by rounding off the ORs and assigning 1
to the reference category. Point scores of 8, 4, and 2 were
assigned for ages > 70, 60-69, 40-59 years; 3 points for
each of diabetes and history of kidney stone, and 2 points
for hypertension. Total scores ranged from 4 to16 and
the score discriminative ability was 77.0%, as shown in
Figure 1. The goodness of fit was assessed and found the
final model was fit well with our data (F test = 3.02, p =
0.264). For ease of use and simplicity, the range of scores
was classified into 4 groups according to LR
+ ; scores of 4-
5, 6-8, 9-11, and ≥ 12 correspond to low, intermediate-
low, intermediate-high, and high probabilities of having
CKD with the LR
+ of 1, 2.5 (95% CI: 2.2-2.7), 4.9 (95% CI:
3.9 - 6.3), and 7.5 (95% CI: 5.6 - 10.1), respectively. The
post-test probability was estimated using the prevalence of
CKD as 17.5% (95% CI: 14.6%-20.2%) according to find-
ings from our previous study [10], as detailed in table 3.
An illustrative example of using the scheme is as follows:
A patient aged 55 years, with history of diabetes and
hypertension but no history of kidney stone, would be
scored as 2 + 3 + 2 + 0 = 7; this is categorized as an inter-
mediate-low risk of having CKD. Assuming a baseline pre-
valence (pre-test probability) of CKD of 14.6 to 20.4%, the
post-test probability is ~29% to 40%.
Validation phase
Two-hundred repetitions of bootstrap were performed
and the logit model contained 4 variables shown in
table 2 which was constructed for each bootstrap. The
estimated Somer’D correlation coefficeints for the origi-
nal and the bootstrap models were 0.544 and 0.499,
respectively. Calibration of the model was assessed by
subtracting the two Somer’s D correlation coefficients,
and it was found that the bias, according to a difference
in observed versus predicted values, was only 0.045
(95% CI:0.034, 0.057). The C statistic of the derivative
and validated models were very much similar, i.e., 0.770
and 0.741. The average difference (known as degree of
optimism) was 0.029. This suggested that the score can
fairly accurately discriminate CKD from non-CKD if it
is applied to a general population whose life styles are
similar to the Thai general population.
Discussion
We have developed and validated a simplified clinical
prediction score for classifying populations into mild,
intermediate-low, intermediate-high, and high risks of
developing CKD. The score was made easier and simpli-
fied using factors that were readily available and simply
assessed in clinical practice. The score shows good cali-
bration and discrimination, as it can be seen from a
similarity between observed and predicted values, as
well as between the C statistic in the derivative and vali-
dation phases, respectively.
We mainly focus on estimating risk of developing CKD,
not CKD progression. Our study has strengths in research
methods as commented in detail in Ingsathit et al[10]. It is
derived from a large number of subjects who were
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Page 3 of 8Table 1 Patient characteristics between CKD and Non-CKD groups
Factors Total (%*) CKD OR (95% CI) p-value
Stage I-V Normal
number % Number %
Age 45.2 (0.79) **
≥ 70 267 (7.7) 139 22.3 128 4.1 14.8 (8.5,26.0) <0.001
60 - 69 403 (11.8) 148 22.9 255 9.4 6.6 (4.2,10.3) <0.001
40 - 59 1464 (43.0) 237 39.2 1,227 43.8 2.4 (1.8, 3.3) 0.001
< 40 1325 (37.9) 102 15.7 1,223 42.7 1
Gender
Male 1569 (45.5) 356 57.8 1,534 53.9 1.2 (0.9, 1.6) 0.253
Female 1890 (54.5) 270 42.2 1,299 46.1 1
BMI 24 (0.2)**
≥ 30 285 (8.9) 65 11.7 220 8.3 1.6 (1.2, 2.2) 0.014
25 - 29.9 924 (27.3) 191 30.5 733 26.6 1.3 (1.0, 1.7) 0.045
< 25 2250 (63.9) 370 57.8 1,880 65.1 1
Waist/Hip 0.84 (0.01) **
Male: Female:
≥ 0.96 ≥ 0.90 354 (9.3) 117 18.6 237 7.4 2.9 (1.7, 4.8) 0.004
< 0.96 < 0.90 3104 (90.7) 509 81.4 2,595 92.6 1
Smoking
Yes 1251 (35.9) 232 36.4 1,019 35.8 1.0 (0.7, 1.5) 0.864
No 2194 (64.1) 391 63.6 1,803 64.2 1
Alcohol consumption
Yes 2084 (59.0) 326 49.5 1,758 61.0 1.6 (1.0, 2.5) 0.044
No 1360 (41.0) 299 50.5 1,061 39.0 1
Exercise
Yes 2057 (59.8) 380 61.9 1,677 59.4 1.1 (0.9, 1.3) 0.164
No 1390 (40.1) 242 38.1 1,148 40.6 1
Work involving significant activity
Yes 2,115 (57.9) 323 49.2 1,792 59.9 1.5 (1.1, 2.1) 0.016
No 1,296 (42.0) 297 50.8 999 40.1 1
DM
Yes 434 (11.9) 183 28.5 251 8.4 4.3 (2.9, 6.6) <0.001
No 3,025 (88.1) 443 71.5 2,582 91.6 1
Hypertension
Yes 955 (27.5) 329 53.6 626 22.0 4.1 (2.9, 5.7) <0.001
No 2,504 (72.5) 297 46.4 2,207 78.0 1
High cholesterol
Yes 851 (26.4) 203 34.3 648 24.7 1.6 (1.2, 2.1) 0.007
No 2,608 (73.6) 423 65.7 2,185 75.3 1
Kidney stone
Yes 169 (5.0) 74 11.3 95 3.7 3.3 (2.1, 5.2) 0.001
No 3,085 (95.0) 516 88.7 2,569 96.3 1
LDL
≥ 160 591 (19.2) 116 20.9 475 18.8 1.1 (0.8, 1.6) 0.490
130-159 807 923.3) 134 21.4 673 23.7 0.9 (0.7, 1.1) 0.263
< 130 1979 (57.5) 359 57.7 1,620 57.5 1
Uric acid
> 5.61 1,269 (38.6) 331 55.0 938 35.1 2.7 (1.8, 4.0) 0.001
4.40-5.61 1,126 (32.3) 166 26.6 960 33.5 1.4 (0.9, 2.1) 0.123
< 4.40 1,064 (29.1) 129 18.4 935 31.4 1
Traditional medicine
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Thailand. In addition, we have validated the clinical pre-
diction score using a 200-repetition bootstrap technique,
which is considered a good technique for internal valida-
tion [15-17]. The C statistic of the simplified score was fair
in both derivative and bootstrap data (i.e., 0.77 and 0.74),
indicating that the score can well discriminate between
CKD and non-CKD subjects. Our model is simplified and
should be easily to apply in clinical practice because of
required variables are routinely measured. The scoring
scheme should be able to apply manually by clinicians and
then the score is classified into 4 groups without requiring
any calculation.
We however have some limitations. Our design was a
cross-sectional survey study and thus the temporal
sequence between risk factors and CKD was question-
able[18]. External validation has not been performed
and generalizability of our prediction model is still
needed to determine. Given good represent samples
across the country, the model might work well in out-
side the studied areas in Thailand, or in other countries
w h e r ep r e v a l e n c eo fd i a b e t e s( ~ 1 1 . 9 % ) ,h y p e r t e n s i o n
(27.5%), and kidney stone (5.0%) are similar to Thai
population. The overly-optimistic predictions in other
populations might be less likely because of an optimistic
rate from the bootstrap is only 2.9%.
To our knowledge, only a few previous prediction
scores [3-5,19] for kidney diseases were available in prior
literature. The study by Hemmelgarn et al [4] had devel-
oped a clinical index for rapid progression of kidney
function, which was defined as a decline in eGFR of 25%
or greater. Five predictors were included in the clinical
index, which were age, heart disease, diabetes, gout, and
the use of anti-emetic drugs. Comparatively, in our study,
only two predictors (i.e., age and diabetes) were similar,
but the others were not significantly associated with
CKD and thus were not considered. The ability of the
score to correctly discriminate those individuals with and
without CKD from our study was fair (area under ROC =
0.77) but it was low for this study (area under ROC =
0.59). Bang et al[3] had well developed scores based on a
cross-sectional NHANES 1999-2000 & 2001-2002 data.
The performance of their scores had also been both
internally and externally tested with good and fair perfor-
mances (i.e., the C statistic were 0.88 and 0.71, respec-
tively). A suggestion of using the score in clinical practice
was also discussed. However, applying a score with a
required 9 input variables (i.e., age, female, anemia,
hypertension, diabetes, history of cardiovascular disease,
congestive heart failure, peripheral vascular disease, and
proteinuria) in clinical practice might not be as simple as
suggested. Data for a history of cardiovascular disease,
Table 1 Patient characteristics between CKD and Non-CKD groups (Continued)
Yes 1,143 (33.5) 263 42.6 880 31.5 1.6 (1.4, 1.9) 0.001
No 2,300 (66.5) 361 57.4 1,939 68.5 1
NSAIDs
Yes 1,577 (44.7) 308 48.3 1,269 43.9 1.2 (0.8, 1.7) 0.266
No 1,882 (55.3) 318 51.7 1,564 56.1 1
*A sampling weight was applied to calculate percentage, ** mean (SE)
Table 2 Factors associated with CKD and creating a scoring scheme: Multiple logistic regression analysis
Factors Coefficient SE P-value OR (95% CI) Scoring Score for individual
Age
≥ 70 2.1 0.22 <0.001 8.3 (4.7, 14.4) 8
60 - 69 1.4 0.17 <0.001 4.1 (2.6, 6.3) 4
40 - 59 0.6 0.13 0.007 1.8 (1.3, 2.5) 2
< 40 1 1 ........................
Kidney stone
Yes 1.0 0.15 0.001 2.8 (1.9, 4.1) 3
No 1 1 .....................
DM
Yes 0.9 0.19 0.005 2.5 (1.5, 4.1) 3
No 1 1 ........................
Hypertension
Yes 0.8 0.13 0.002 2.3 (1.6, 3.2) 2
No 1 1 ........................
Total score 4-16 ........................
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Page 5 of 8congestive heart failure, and peripheral vascular disease
may not be valid in developing countries where popula-
tions have a limited understanding of the diseases they
have been diagnosed with. The ability of discrimination
for this score in Asians may not be valid since the preva-
lence of CKD in Caucasian vs. Asian populations is quite
different [20], and also lifestyle factors that directly or
i n d i r e c t l yi n f l u e n c eC K Dm a yb em a r k e d l yd i f f e r e n t .
Kshirsagar et al[5] conducted a study on a community-
based cohorts with ages of 45 years or older in order to
create the best fitting and simplified scores for predicting
the incidence of CKD (GFR < 60 ml/min/1.73 m
2). The
study design was better than previous studies in terms of
the predictor-CKD causal relationship, which could
be assessed for the cohort study. Two prediction score
models were proposed, one with, the full score of 10 pre-
dictors (i.e., age, white ethnicity, female, anemia, hyper-
tension, diabetes, history of cardiovascular disease,
history of heart failure, low HDL, and peripheral vascular
disease), and a simplified score with 8 predictors, omit-
ting two variables, ethnicity and HDL. Again, applying
either the best fitting or the reduced model may not so
simple since so many variables are required to input in
the models. Creating a score by rounding up a coefficient
to the nearest integer (higher than estimated) was not
clearly described in the paper. For instance, estimated
coefficients for ages 60-69 and ≥ 70 years of 1.31 and
1.46 respectively were round e du pt ob e2a n d3i n s t e a d
of rounding down to 2 and 2. In addition, coefficients of
other variables that were less than 1 (e.g., 0.2-0.6) were
rounded up to be equal to a score of 1 and thus given an
equal weight of contribution to the total scores. This
would raise the question, for example, of whether gender
played the same role as hypertension. The clinical predic-
tion scores for diabetes have also been used for predict-
ing CKD[6]. As expected, the discrimination was low,
ranging from 0.60 to 0.71, and generalizability was
questionable.
Using the clinical prediction score in practice
Using only one cut-off (e.g., according to Yuden’si n d e x
(sensitivity + specificity - 1)[21,22]) classifies subjects too
broadly and thus does not work for this prediction score.
For instance, applying Yuden’s index resulted in a cut-off
of 5 which provided the highest sensitivity and specificity
(i.e., 76% and 69%, respectively). This would also result in
a very large screening of serum creatinine across the
country if a suggestion were based on this cutoff. In a
country with limited resources, scoring should be priori-
tized with meaningful and clinical relevance. The predic-
tion scores are thus classified into four groups according
to the LR
+ which are: low (4-5); intermediate-low (6-8);
intermediate-high (9-11); and high (≥12). The variables
used are easily obtained and measurable in general prac-
tice; hence, a general practitioner, an internist, or even a
nephrologist should be able to manually apply prediction
scores in routine bedside-practice. Interpreting LR
+ is
more informative using a nomogram, which is widely
used in diagnostic test results [23]. For instance, in data
from a medical record or physical examination, if a sub-
ject is younger than 40 years with high blood pressure,
no history of diabetes and history of kidney stones, and
normal blood sugar, this would give the patient a score of
5, corresponding to a LR
+ of 1. Assuming a baseline pre-
valence (pre-test probability) of CKD ranging from 17.5%
(95% CI: 14.6%- 20.2%)[10], the post-test probability of
this person is ~17.5% (95% CI: 15%-20%). This patient is
in a low risk group and thus can be checked for kidney
function once a year, if and only if he/she does not
develop other risks, e.g., diabetes or history of kidney
stones. If the patient later develops diabetes and/or kid-
ney stones, this would give him/her a score of 6-8, corre-
sponding to a LR
+ of 2.5 and the post-test odds would be
0
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Figure 1 Performance of a clinical prediction score of CKD:
ROC curve analysis.
Table 3 Predictive values of a clinical prediction score
Score Sensitivity (%) Specificity (%) +LR (95% CI) Post-test probability (95% CI)
*
4-5 100.0 0 1 17.5% (15%-20%)
6-8 76.1 68.8 2.5(2.2-2.7) 35% (29%-40%).
9-11 33.4 93.2 4.9 (3.9 - 6.3) 50% (45%-55%)
≥ 12 17.9 97.6 7.5 (.6 - 10.1) 60% (55%-65%)
*Based on CKD prevalence of 17.5% and its 95% CI of 14.6% - 20.4%
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Page 6 of 80.530 (i.e., a pre-test odds × LR
+ = 0.175/(1-0.175) × 2.5).
This resulted in the post-test probability of ~35% (95%
CI: 29%-40%, which could be estimated by post-test
odds/(1+post-test odds). Monitoring kidney function by
measuring both serum creatinine and urine albumin
should be more frequent than a score of 5, say twice a
year. Subject ages < 40 to 59 years having all 3 risks
would have scores of 9-11, giving a LR
+ of 4.9 which
would result in a post-test probability of ~50% (95% CI:
45%-55%). If he/she is getting older, say age ≥ 60 years,
the score is 12 with LR
+ of ~7, resulting in a post-test
probability of ~60% (95% CI: 55%-65%). These two scores
give intermediate-high and high probabilities of having
CKD, and thus indicating more frequent follow-ups, say
3-4 times a year. Treatments for diabetes and hyperten-
sion should be also intensified according to guideline of
treatments to control disease conditions. As a result, risk
of developing CKD is lowering or once it occurs, delay
progression of CKD will be targeted.
Conclusion
We propose a simple clinical prediction score of CKD to
aid general practitioners, internists, or nephrologists in
identifying CKD in the general population. Practioners
should be encouraged to use the score in routine clinical
practice in order to make a more concerted effort in the
identification and early treatment of CKD. Vigilant
monitoring should be planned to prevent the develop-
ment of CKD and delay higher stages if it happens. In
the long run, this prediction score will be of benefit to
the country if end-stage kidney disease can be reduced.
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